Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Mallinckrodt
McKesson
Merck
Baxter

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020895

See Plans and Pricing

« Back to Dashboard

NDA 020895 describes VIAGRA, which is a drug marketed by Pfizer Inc and is included in one NDA. It is available from ten suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the VIAGRA profile page.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.
Summary for 020895
Tradename:VIAGRA
Applicant:Pfizer Inc
Ingredient:sildenafil citrate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 020895
Medical Subject Heading (MeSH) Categories for 020895
Suppliers and Packaging for NDA: 020895
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIAGRA sildenafil citrate TABLET;ORAL 020895 NDA Pfizer Laboratories Div Pfizer Inc 0069-4200 0069-4200-30 30 TABLET, FILM COATED in 1 BOTTLE (0069-4200-30)
VIAGRA sildenafil citrate TABLET;ORAL 020895 NDA Pfizer Laboratories Div Pfizer Inc 0069-4210 0069-4210-30 30 TABLET, FILM COATED in 1 BOTTLE (0069-4210-30)
Paragraph IV (Patent) Challenges for 020895
Tradename Dosage Ingredient NDA Submissiondate
VIAGRA TABLET;ORAL sildenafil citrate 020895 2004-11-19
VIAGRA TABLET;ORAL sildenafil citrate 020895 2004-10-25

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 25MG BASE
Approval Date:Mar 27, 1998TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Apr 22, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 50MG BASE
Approval Date:Mar 27, 1998TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Apr 22, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 100MG BASE
Approval Date:Mar 27, 1998TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Apr 22, 2020Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 020895

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998   Start Trial   Start Trial
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998   Start Trial   Start Trial
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKesson
Johnson and Johnson
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.